Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites

Cancer Research

Volumn 61, Issue 23, 2001, Pages 8569-8577

  Guo, Ping ^a   Xu, Li ^a   Pan, Shi ^a   Yang, Shu Ting ^a   Cheng, Shi Yuan ^a   Brekken, Rolf A ^b   Whitaker, G Brian ^c   Rosenbaum, Jan S ^c   Thorpe, Philip E ^d   Nagane, Motoo ^e   Huang, H J Su ^e   Cavenee, Webster K ^e  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b HOPE HEART INSTITUTE   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VITRONECTIN;

ARTICLE; BRAIN HEMORRHAGE; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GLIOMA; HUMAN; HUMAN CELL; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULARIZATION;

ANIMALS; BRAIN NEOPLASMS; CELL MOVEMENT; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GLIOMA; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITRONECTIN;

EID: 0035577770     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Vascular endothelial growth factor: Molecular and biological aspects
2. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice
3. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
4. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
5. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression
6. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
7. Impact of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
8. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-I
9. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis
10. 189
11. The splice variants of vascular endothelial growth factor (VEGF) and their receptors
12. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
13. Expression of cell-associated isoform of vascular endothelial growth factor 189 and its prognostic relevance in non-small cell lung cancer
14. Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon
15. Vascular endothelial growth factor-induced tumor angiogenesis and tumorigenicity in relation to metastasis in a HT1080 human fibrosarcoma cell model
16. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo
17. 188
18. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1. KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors
19. Vascular endothelial growth factor as a marker of tumor endothelium
20. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
21. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
22. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145- amino acid form of VEGF
23. Roles of a neuronal cell-surface molecule, neuropilin, in nerve fiber fasciculation and guidance
24. A requirement for neuropilin-1 in embryonic vessel formation
25. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs
26. Neuropilin is a semaphorin III receptor
27. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity
28. Genomic organization of human neuropilin-1 and neuropilin-2 genes: Identification and distribution of splice variants and soluble isoforms
29. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
30. Integrins: Versatility, modulation, and signaling in cell adhesion
31. Glioblastoma expression of vitronectin and the a v β 3 integrin. Adhesion mechanism for transformed glial cells
32. Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors
33. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins
34. The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
35. VEGF gene therapy: Stimulating angiogenesis or angioma-genes?
36. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature
37. Vascular endothelial growth factor and its receptors, fit-1 and flt-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis
38. FIt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
39. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer
40. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR-1 and VEGFR-2 in vivo
41. The role of av integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
42. Preferential susceptibility of brain tumors to the antiangiogenic effects of an a(v) integrin antagonist
43. Human malignant glioma therapy using anti-α(v)β3 integrin agents
44. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice
45. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells
46. Extracellular matrix composition determines the transcriptional response to epidermal growth factor receptor activation
47. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. Subcutaneous tumors